Altimmune Announces Positive Results from NasoVAX Extension Study
Seroprotective HAI antibody response persisted more than one year after vaccination
Company seeking partnership for further development and commercialization of NasoVAX
Subjects from the highest dose group of the study were invited to return as part of a study extension to evaluate the duration of immunity 1-year post-vaccination. Of 15 subjects invited, 8 returned an average of 13.5 months after vaccination. Antibody titers for all 8 subjects remained seroprotective, with a median hemagglutination inhibition (HAI) titer more than 3-times higher than generally accepted seroprotective levels. Coupled with previously demonstrated mucosal antibody and T-cell related correlates of immunoprotection, NasoVAX is well positioned to compete with other influenza vaccines currently under development.
“We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market,” said
NasoVAX, an intranasally administered recombinant influenza vaccine, uses an adenovector to achieve expression of the influenza antigen in the target cell, thereby potentially stimulating a broader and more rapid immune response than traditional influenza vaccines. Our Phase 2a trial evaluating NasoVAX started in
|Vipin K. Garg, Ph.D.
President and CEO
Managing Director LifeSci Advisors
Source: Altimmune, Inc.